“`html
The average one-year price target for Arrowhead Pharmaceuticals (NASDAQ: ARWR) has been revised to $59.24 per share as of November 14, 2025, representing an increase of 17.24% from the previous estimate of $50.53. The new price target ranges from a low of $17.17 to a high of $89.25 per share, while the average target indicates a decrease of 3.58% from the latest closing price of $61.44 per share.
As of the last quarter, 546 institutional funds are reporting positions in Arrowhead Pharmaceuticals, an increase of 4.60%. Total shares owned by institutions rose by 4.20% to 130,072K shares, with an average portfolio weight of 0.14%—up by 37.97%. The put/call ratio for ARWR stands at 0.33, implying a bullish sentiment.
Prominent shareholders include Avoro Capital Advisors, owning 10,900K shares (8.03% ownership, up 2.75%), and IJR – iShares Core S&P Small-Cap ETF with 7,520K shares (5.54% ownership, down 4.26%). Other notable holders include Slate Path Capital and Vanguard Total Stock Market Index Fund, both increasing their portfolios by significant percentages over the last quarter.
“`
